Rachel Rhinehart
Medical · Jefferson, LANPI 1780212605
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amneal Pharmaceuticals LLC accounts for 75.2% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $13,499, more than ten times the $381 reported in 2021. Among medical clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $126.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$12K
- AbbVie$1K
- Acadia Pharmaceuticals Inc$977
- Teva Pharmaceuticals USA, Inc.$538
- Neurocrine Biosciences, Inc.$346
- Ipsen Biopharmaceuticals, Inc$203
- plus $639 from 9 others
What the payments were for
- Consulting fees$2502%
- Speaking & faculty fees$8,16051%
- Travel & lodging$2,33615%
- Food & beverage$4,07125%
- Education$1,1747%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 19 | $12,032 |
| AbbVie | 42 | $1,255 |
| Acadia Pharmaceuticals Inc | 17 | $977 |
| Teva Pharmaceuticals USA, Inc. | 11 | $538 |
| Neurocrine Biosciences, Inc. | 12 | $346 |
| Ipsen Biopharmaceuticals, Inc | 3 | $203 |
| MDD US Operations, LLC | 5 | $192 |
| GE HealthCare | 5 | $113 |
| Kyowa Kirin, Inc. | 2 | $95 |
| Merz Pharmaceuticals, LLC | 3 | $60 |
| Biogen | 2 | $49 |
| Eisai Inc. | 2 | $38 |
| Amgen | 1 | $35 |
| UCB, Inc. | 1 | $32 |
| Boston Scientific | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,990 in reported general payments places this provider in the 95th percentile of 253 medical providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 71 | $479,268 |
| RytaryCarbidopa/Levodopa | 146 | $205,312 |
| IngrezzaValbenazine Tosylate | 25 | $194,900 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $135,982 |
| Austedo XrDeutetrabenazine | 18 | $122,295 |
| NuplazidPimavanserin Tartrate | 19 | $94,566 |
| NourianzIstradefylline | 17 | $53,987 |
| Droxidopa | 35 | $38,279 |
| Rasagiline Mesylate | 217 | $34,473 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,328 | $32,540 |
| BelsomraSuvorexant | 49 | $21,069 |
| NeuproRotigotine | 17 | $14,134 |
| Selegiline Hcl | 93 | $14,035 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 19 | $7,427 |
| Carbidopa | 39 | $6,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $538 | $601,56389 claims |
| Amneal Pharmaceuticals LLCRytary | $12,032 | $205,312146 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $346 | $194,90025 claims |
| Acadia Pharmaceuticals IncNuplazid | $977 | $94,56619 claims |
| Kyowa Kirin, Inc.Nourianz | $95 | $53,98717 claims |
| UCB, Inc.Neupro | $32 | $14,13417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 medical providers in Louisiana.
Other medical in Jefferson
- Jason AmadeoJefferson$3K
- Kristi RobertBaton Rouge$486K
- Vickie RiceBaton Rouge$19K
- Mary McFerrenShreveport$16K
- Sydney FussellCovington$16K
- Thomas BriscoeLafayette$13K
- Seth HendrixShreveport$12K
- Jessica PelusoNatchitoches$12K
- Heather RoanBossier City$11K
- Emily FerraraBaton Rouge$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.